Researchers used computer modeling to estimate the number of deaths that could be prevented, and the harms caused, if more people used USPSTF-recommended cancer screening tests. The study’s lead investigator, Dr. Amy Knudsen, explains the findings.
Some people with no evidence of cancer in nearby lymph nodes after presurgical chemotherapy can skip radiation to that area without increasing the risk of the cancer returning, a clinical trial found. But some experts caution that more details are needed.
Adding daratumumab (Darzalex) to standard treatment helped people with newly diagnosed multiple myeloma live longer without their cancer getting worse or dying. People taking daratumumab were also more likely to have no detectable signs of cancer (minimal residual disease) after treatment.
In a recent study, more than 90% of people who’d had their stomach surgically removed to prevent cancer experienced a least one chronic complication 2 years out from their surgery. For some, the complications are life altering.
Under a new FDA approval, enzalutamide (Xtandi) can now be used alone, or in combination with leuprolide, to treat people with nonmetastatic prostate cancer that is at high risk of returning after surgery or radiation.